Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(4):193-8
Article Links
Update on Sjögren’s Syndrome 2018
Ourania D. Argyropoulou, Athanasios G. Tzioufas
Authors Information

Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece

Keywords: Sjögren’s syndrome, pathogenesis, germinal centres, salivary gland ultrasonography, treatment
References
  1. Mavragani CP. Mechanisms and New Strategies for Primary Sjögren’s Syndrome. Ann Rev Med 2017;68:331-43. [https://doi.org/10.1146/annurev-med-043015-123313] [PMID: 28099084]
  2. Fogel O, Rivière E, Seror R, Nocturne G, Boudaoud S, Ly B, et al. Role of the IL-12/IL35 balance in patients with Sjögren syndrome. J Allergy Clin Immunol 2018;142:258-68. [https://doi.org/10.1016/j.jaci.2017.07.041] [PMID: 28916184]
  3. Nilsson AM, Tufvesson E, Hesselstrand R, Olsson P, Wollmer P, Mandl T. Increased B-cell activating factor, interleukin-6, and interleukin-8 in induced sputum from primary Sjögren's syndrome patients. Scand J Rheumatol 2018 Sep 30:1-8. [Epub ahead of print]. [https://doi.org/10.1080/03009742.2018.1473488] [PMID: 30270699]
  4. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 2013; 45:1284-92. [https://doi.org/10.1038/ng.2792] [PMID: 24097067] [PMCID: PMC3867192]
  5. Argyropoulou OD, Valentini E, Ferro F, Leone MC, Cafaro G, Bartoloni E, Baldini C. One year in review 2018; Sjögren’s syndrome. Clin Exp Rheumatol 2018;36(Suppl. 112):14-26.
  6. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, Maria NI, Tarn J, Lendrem DW, et al. Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. Rheumatology (Oxford) 2018;57(5):921-30. [https://doi.org/10.1093/rheumatology/kex490] [PMID: 29474655]
  7. Davies R, Hammenfors D, Bergum B, Vogelsang P, Gavasso S, Brun JG, et al. Aberrant cell signaling in PBMCs upon IFN-alpha stimulation in primary Sjögren’s syndrome patients associates with type I interferon signature. Eur J Immunol 2018;48:1217-27. [https://doi.org/10.1002/eji.201747213] [PMID: 29604049]
  8. Antiochos B, Matyszewski M, Sohn J, Casciola-Rosen L, Rosen A. IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in Sjögren's syndrome. JCI Insight 2018;3(18) [Epub ahead of print]. [https://doi.org/10.1172/jci.insight.120179] [PMID: 30232276] [PMCID: PMC6237237]
  9. Imgenberg-Kreuz J, Sandling JK, Björk A, Nordlund J, Kvarnström M, Eloranta ML, et al. Transcription profiling of peripheral B cells in antibody- positive primary Sjögren’s syndrome reveals upregulated expression of CX3CR1 and type I and type II interferon signature. Scand J Immunol 2018;87:e12662. [https://doi.org/10.1111/sji.12662]  [PMID: 29655283]
  10. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol 2018;14(3):133-45. [https://doi.org/10.1038/nrrheum.2018.1] [PMID: 29416129]
  11. Barcelos F, Martins C, Papoila A, Geraldes C, Cardigos J, Nunes G, et al. Association between memory B-cells and clinical and immunological features of primary Sjögren’s syndrome and Sicca patients. Rheumatol Int 2018;38:1063-73. [https://doi.org/10.1007/s00296-018-4018-0] [PMID: 29623391]
  12. Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK. Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. J Autoimmun 2018;88:75-82. [https://doi.org/10.1016/j.jaut.2017.10.004] [PMID: 29074164]
  13. Imgenberg-Kreuz J, Sandling JK, Nordmark G. Epigenetic alterations in primary Sjögren’s syndrome-an overview. Clin Immunol 2018 (pii: S1521-6616(18)30020-2). [Epub ahead of print]. [https://doi.org/10.1016/j.clim.2018.04.004] [PMID: 29649576] 
  14. Wang-Renault SF, Boudaoud S, Nocturne G, Roche E, Sigrist N, Daviaud C, et al. Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren’s syndrome. Ann Rheum Dis 2018;77:133-40. [https://doi.org/10.1136/annrheumdis-2017-211417] [PMID: 28916716] [PMCID: PMC5754740]
  15. Johansson A, Nyberg WA, Sjöstrand M, Moruzzi N, Bergman P, Khademi M, et al. miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome. Eur J Immunol. 2018 Oct 11 [Epub ahead of print]. [https://doi.org/10.1002/eji.201747416] [PMID: 30307034]
  16. Wang Y, Zhang G, Zhang L, Zhao M, Huang H, et al. Decreased microRNA-181a and -16 expression levels in the labial salivary glands of Sjögren syndrome patients. Exp Ther Med 2018;15:426-32. [https://doi.org/10.3892/etm.2017.5407] [PMID: 29387196] [PMCID: PMC5769212]
  17. Weng X, Liu Y, Cui S, Cheng B. The role of RORα in salivary gland lesions in patients with primary Sjögren's syndrome. Arthritis Res Ther 2018;20(1):205. [https://doi.org/10.1186/s13075-018-1698-5] [PMID: 30189901] [PMCID: PMC6127992]
  18. Shah NR, Noll BD, Padilla RJ, Brennan MT, Mougeot FB, Mougeot JC. Expression of ETS1 and LEF1 in Salivary Glands of Sjögren Syndrome patients. Oral Dis 2018 Oct 1 [Epub ahead of print]. [https://doi.org/10.1111/odi.12985] [PMID: 30270548]
  19. Chen Y, Wang Y, Xu L, Zhu W, Xu C, Xu M, et al. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome. Int J Rheum Dis 2018 Oct 18 [Epub ahead of print]. [https://doi.org/10.1111/1756-185X.13391] [PMID: 30338648]
  20. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against classification criteria for primary Sjögren’s syndrome. A consensus and data-driven methodology involving three international patient cοhort. Ann Rheum Dis 2017;76:9-16. [https://doi.org/10.1002/art.39859] [PMID: 27785888] [PMCID: PMC5650478]
  21. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM, et al. Germinal centres in diagnostic biopsies of pSS patients are not a risk factor for non-Hodgkin's lymphoma but a reflection of high disease activity. Arthritis Rheumatol 2018 Sep 3 [Epub ahead of print]. [https://doi.org/10.1002/art.40715] [PMID: 30178631]
  22. Sène D, Ismael S, Forien M, Charlotte F, Kaci R, Cacoub P, Diallo A, et al. Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome. Arthritis Rheumatol 2018;70(9):1481-8. [https://doi.org/10.1002/art.40528] [PMID: 29669392]
  23. Vacrakou AG, Boiu S, Ziakas PD, Xingi E, Boleti H, Manoussakis MN. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjögren’s syndrome fueled by inflammagenic DNA accumulations. J Autoimmun 2018;91:23-33. [https://doi.org/10.1016/j.jaut.2018.02.010] [PMID: 29551295]
  24. Lee KA, Lee SH, Kim HR. Diagnostic and predictive evaluation using salivary gland ultrasonography in primary Sjögren’s syndrome. Clin Exp Rheumatol 2018;36 Suppl 112(3):165-72. [PMID: 29600950]
  25. Mossel E, Arends S, van Nimwegen JF, Delli K, Stel AJ, Kroese FGM, et al. Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren’s syndrome. Ann Rheum Dis 2018;77:556-62. [https://doi.org/10.1136/annrheumdis-2017-211992] [PMID: 29233833]
  26. Gazeau P, Cornec D, Jousse-Joulin S, Guellec D, Saraux A, Devauchelle-Pensec V. Time-course of ultrasound abnormalities of major salivary glands in suspected Sjögren’s syndrome. Joint Bone Spine 2018;85:227-32. [https://doi.org/10.1016/j.jbspin.2017.02.007] [PMID: 28249724]
  27. Akiyama M, Sasaki T, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, et al. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren’s syndrome adults from a defined population. Clin Exp Rheumatol 2018;36 Suppl 112(3):157-64. [PMID: 29465360]
  28. Molano-González N,  Olivares-Martínez E, Anaya JM, Hernández-Molina G. Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analysis. Scand J Rheumatol 2018 Sep 30:1-7 [Epub ahead of print]. [https://doi.org/10.1080/03009742.2018.1469164] [PMID: 30270696]
  29. Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. Clin Exp Rheumatol 2018;36 Suppl 112(3):94-101. [PMID: 29846161]
  30. Cinoku I, Mavragani CP, Tellis CC, Nezos A, Tselepis AD, Moutsopoulos HM. Autoantibodies to ox-LDL in Sjögren’s syndrome: are they atheroprotective? Clin Exp Rheumatol 2018;36 Suppl 112(3):61-7. [PMID: 30156537]
  31. Karageorgas T, Ioakeimidis D, Mavragani CP. Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjögren's syndrome: a potential contribution of sleep impairment. Clin Exp Rheumatol 2018;36 Suppl 112(3):68-72. [PMID: 29148412]
  32. Birnbaum J, Lalji A, Saed A, Baer AN. Biopsy-Proven Small-Fiber Neuropathy in Primary Sjögren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathological Features. Arthritis Care Res (Hoboken). 2018 Sep 17 [Epub ahead of print]. [https://doi.org/10.1002/acr.23762] [PMID: 30221483]
  33. Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and lymphomagenesis in Primary Sjögren’s Syndrome. Front Med (Lausanne) 2018 Apr 13;5:102. [https://doi.org/10.3389/fmed.2018.00102] [PMID: 29707540] [PMCID: PMC5909032]
  34. Kapsogeorgou ΕΚ, Papageorgiou A, Protogerou AD, Voulgarelis M, Tzioufas AG. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren’s syndrome. Ann Rheum Dis 2018;77(8):1200-7. [https://doi.org/10.1136/annrheumdis-2017-212639] [PMID: 29779010]
  35. Othman TM, Mousa A, Gikandi PW, AbdelMabod M, Abdelrahman AM. Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease. Saudi J Ophthalmol 2018;32(3):217-21. [https://doi.org/10.1016/j.sjopt.2018.06.001] [PMID: 30224886] [PMCID: PMC6137823]
  36. Del Papa N, Vitali C. Management of primary Sjögren's syndrome: recent developments and new classification criteria. Ther Adv Musculoskelet Dis 2018;10(2):39-54. [https://doi.org/10.1177/1759720X17746319] [PMID: 29387177] [PMCID: PMC5784475]
  37. Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2018;26:1-8. [https://doi.org/10.1080/17843286.2018.1521904] [PMID: 30253707]
  38. Fischer BA, Everett CC, Rout J, O'Dwyer JL, Emery P, Pitzalis C, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’syndrome: results of the TRACTISS randomized double-blind multicenter substudy. Ann Rheum Dis 2018;77:412-6. [https://doi.org/10.1136/annrheumdis-2017-212268] [PMID: 29275334] [PMCID: PMC5867400]
  39. Barsalou J, Costedoat-Chalumeau N, Berhanu A, Fors-Nieves C, Shah U, Brown P, et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis 2018 Oct 8 [Epub ahead of print]. [https://doi.org/10.1136/annrheumdis-2018-213718] [PMID: 30297329]
  40. Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjögren's syndrome: why? Clin Exp Rheumatol 2018;36 Suppl 112(3):27-8. [PMID: 29998826]
  41. Bombardieri M, Baldini C, Alevizos I, Akpek E, Baer AN. Highlights of the 14th International Symposium in Sjögren's Syndrome. Clin Exp Rheumatol 2018;36 Suppl 112(3):3-13. [PMID: 30156541]
  42. St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2018;70(9):1470-80. [https://doi.org/10.1002/art.40513] [PMID: 29604186] [PMCID: PMC6115299]
  43. Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, et al. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. Arthritis Rheumatol 2018;70(5):763-73. [https://doi.org/10.1002/art.40425] [PMID: 29381843] [PMCID: PMC5947119]